Showing posts with label Epilepsy Market Global Industry medical industry. Show all posts
Showing posts with label Epilepsy Market Global Industry medical industry. Show all posts

Friday 20 April 2018

Epilepsy 2017–By Identifying the Key Market Segments and Key players holding market share

Epilepsy Market
Summary 
Epilepsy is a group of neurological diseases characterized by epileptic seizures. Epileptic seizures are episodes that can vary from brief and nearly undetectable to long periods of vigorous shaking. These episodes can result in physical injuries including occasionally broken bones. The medical definition of this disease is as a “condition characterized by recurrent (two or more) epileptic seizures, unprovoked by any immediate identified cause”. Epilepsy is divided into four main types; idiopathic generalized epilepsy, idiopathic partial epilepsy, symptomatic generalized epilepsy and symptomatic partial epilepsy. The cause of epilepsy can be genetic, a result of other disorders such as tumor or brain injury and due to certain seizure triggers.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/1615864-global-epilepsy-market-industry-analysis-outlook-2017-2021

Report Highlights
Epilepsy is treated via antiepileptic drugs, surgery in certain cases and several complementary therapies such as ketogenic diets or neural stimulation. Based upon the drug type, epilepsy market can be divided into three main categories; first generation drugs, second generation drugs and third generation drugs.
The global epilepsy market is driven by factors such as development of novel drugs, launch of new drugs in developing regions and prevalence of neural disorders such as meningitis and tumors. This growth is then further spearheaded by increasing healthcare expenses and rising disposable incomes. However, the market growth is hindered by tedious drug approval process, generic erosion and high cost of treatment. Trends such as companies focusing on developing effective therapies for refractory epilepsy and physicians demanding higher efficacy drugs are listed in this report.

Table of Contents 
  1. Overview
    1.1 Epilepsy
    1.2 Types of Epilepsy
    1.3 Causes
    1.5 Treatment
    1.6 Epilepsy Market by Drug Class
  1. Global Antiepileptic Market
    2.1 Global Antiepileptic Drugs Market Forecast by Value
    2.2 Global Antiepileptic Drugs Market by Region
    2.3 Global Antiepileptic Market by Drug Type
      2.3.1 Global Branded Antiepileptic Drugs Market Forecast by Value
      2.3.2 Global Generic Antiepileptic Drugs Market Forecast by Value
    2.4 Global Branded Antiepileptic Market by Drug Class
      2.4.1 Global Second Generation Antiepileptic Drugs Market Forecast by Value
      2.4.2 Global Third Gen Branded Antiepileptic Market Forecast by Value
      2.4.3 Global First Generation Antiepileptic Drugs Market Forecast by Value
  1. Regional Markets
    3.1 Americas
      3.1.1 Americas Antiepileptic Drugs Market Forecast by Value
      3.1.2 The US Antiepileptic Drugs Market Forecast by Value
      3.1.3 The US Antiepileptic Drugs Prescription Forecast by Volume
      3.1.4 The US Child Epileptic Patients by Volume
      3.1.5 The US Child Pharmacoresistant Epilepsy Patient by Volume

  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1615864-global-epilepsy-market-industry-analysis-outlook-2017-2021
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)